ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Summary of pivotal studies to qualify for FDA approval

Summary of pivotal studies to qualify for FDA approval
Technique Study Study endpoint Closure rate Adverse events
RFA Proebstle[1] 6 months 99.6%

DVT: 0%

Paresthesia: 3.2%

Phlebitis: 0.8%
VeClose Trial[2] 3 months 96%

DVT: 0%

Paresthesia: 3%

Phlebitis: 3%
Laser ablation Min[3] 2 years 93.4%

DVT: 0%

Paresthesia: 1.1%
PEM (1% POL) VANISH-1[4] 8 week closure rate with 1% polidocanol 80.4%

DVT: 1.9%

Phlebitis: 7.7%
VANISH-2[5] 86.2%  
MOCA Elias[6] 6 months 96.7% No PE or CVA events
Cyanoacrylate glue VeClose Trial 3 months 99% VenaSeal

DVT: 0%

Paresthesia: 3%

Phlebitis: 4%
FDA: Food and Drug Administration; RFA: radiofrequency ablation; DVT: deep vein thrombosis; PEM: polidocanol endovenous microfoam; POL: polidocanol; MOCA: mechanical occlusion with chemical assistance; PE: pulmonary embolism; CVA: cerebrovascular accident.
References:
  1. Proebstle TM, Vago B, Alm J, et al. Treatment of the incompetent great saphenous vein by endovenous radiofrequency powered segmental thermal ablation: First clinical experience. J Vasc Surg 2008; 47:151.
  2. Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg 2015; 61:985.
  3. Min RJ, Zimmet ST, Isaacs MN, Forrestal MD. Endovenous laser treatment of the incompetent greater saphenous vein. J Vasc Interv Radiolology 2001; 12:1167.
  4. King JT, O'Byrne M, Vasquez M, et al. Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. Eur J Vasc Endovasc Surg 2015; 50:784.
  5. Todd KL 3rd, Wright DI, VANISH-2 Investigator Group. The VANISH-2 study: A randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology 2014; 29:608.
  6. Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: Final results of the initial clinical trial. Phlebology 2012; 27:67.
Graphic 119310 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟